Most Read Articles
Prof. Cheuk-Chun Szeto, Dr. Winston W. S. Fung, 25 Jan 2018
A 65-year-old lady with a background of type 2 diabetes, hyperlipidaemia and chronic immune thrombocytopenia presented to us with a 2-week history of generalized malaise and myalgia. Shortly after the onset of myalgia, she was noted to have reduced urine output and the urine was described as dark in colour. Her regular medications included prednisolone, danazol, simvastatin, metformin, and human insulin. Upon further questioning, the patient admitted that her compliance to simvastatin and danazol used to be poor. However, she recently started to take both medications regularly after repeated education.
Pearl Toh, 30 Jan 2018
Use of statins may not be neuroprotective, in contrast to findings from previous observational studies. On the contrary, fungus-derived or lipophilic statins appeared to be associated with a slightly increased risk of Alzheimer's disease (AD) compared with synthetic and hydrophilic statins, suggests a new study based on real-world clinical practice data.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Rachel Soon, 21 Feb 2018

MIMS Pharmacist sits down with pharmacist researcher Dr Mai Chun Wai to find out more about his work in drug discovery, including his investigations of Antarctic soil microorganisms.

Studies demonstrate conflicting findings on impact of obesity on treatment response, outcomes in IBD

Audrey Abella
20 Feb 2018

Obesity does not appear to have a significant influence on treatment response and clinical outcomes in patients with inflammatory bowel disease (IBD), according to two studies presented at the 2018 Crohn’s & Colitis Congress (CCC).

A pooled analysis of the infliximab arms of six trials (n=1,399, mean age 36 years, 52 percent males, 14 percent obese) revealed no association between obesity and the odds of achieving clinical remission (adjusted odds ratio [adjOR], 0.94, 95 percent confidence interval [CI], 0.61–1.47; ptrend=0.97), clinical response (adjOR, 0.84, 95 percent CI, 0.52–1.35; p=0.45), or mucosal healing remission (adjOR, 1.13, 95 percent CI, 0.55–2.34; p=0.95). [2018 CCC, abstract 186]

Furthermore, pooled evaluation of the placebo arms of four trials (n=575, mean age 38 years, 52 percent males, 16 percent obese) revealed similar results, demonstrating a lack of association between obesity and the odds of achieving clinical remission (adjOR, 1.36, 95 percent CI, 0.65–2.89; ptrend=0.57), clinical response (adjOR, 1.31, 95 percent CI, 0.61–2.81; p=0.45), or mucosal healing remission (adjOR, 0.55, 95 percent CI, 0.12–2.34; p=0.31). [2018 CCC, abstract 183]

The findings of these two pooled analyses suggest that obesity does not influence response to the biologic agent infliximab nor does it affect short- and intermediate-term clinical outcomes in patients with IBD, said the researchers.

 

Higher BMI = increased treatment failure

A retrospective study comprising 160 biologic-treated patients (55 percent infliximab) with ulcerative colitis (median age 36 years, 50 percent males) showed conflicting results, demonstrating an association between a higher body mass index (BMI) and an increased risk of treatment failure and surgery. [2018 CCC, abstract 24]

Multivariate analysis revealed that every 1 kg/m2 increase in BMI was associated with an increased risk of treatment failure (adjusted hazard ratio [adjHR], 1.04, 95 percent CI, 1.00–1.08; p=0.034) and surgery or hospitalization (adjHR, 1.08, 95 percent CI, 1.02–1.14; p=0.008), as well as a reduction in achieving endoscopic remission (adjOR, 0.94, 95 percent CI, 0.87–1.00; p=0.070).

The effect on treatment failure was observed among participants receiving fixed-dose (adjHR, 1.05, 95 percent CI, 0.99–1.12; p=0.106) or weight-based dosing regimens (adjHR, 1.05, 95 percent CI, 1.00–1.10; p=0.05).

“[Our findings show that] BMI is independently associated with decreased response to biologic agents in patients [with ulcerative colitis], which may be independent of dosing regimen,” said the researchers of this study.

Given these conflicting findings, further investigation is warranted to elucidate the influence of obesity on treatment response and long-term outcomes in IBD, said the researchers of the two pooled analyses.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Prof. Cheuk-Chun Szeto, Dr. Winston W. S. Fung, 25 Jan 2018
A 65-year-old lady with a background of type 2 diabetes, hyperlipidaemia and chronic immune thrombocytopenia presented to us with a 2-week history of generalized malaise and myalgia. Shortly after the onset of myalgia, she was noted to have reduced urine output and the urine was described as dark in colour. Her regular medications included prednisolone, danazol, simvastatin, metformin, and human insulin. Upon further questioning, the patient admitted that her compliance to simvastatin and danazol used to be poor. However, she recently started to take both medications regularly after repeated education.
Pearl Toh, 30 Jan 2018
Use of statins may not be neuroprotective, in contrast to findings from previous observational studies. On the contrary, fungus-derived or lipophilic statins appeared to be associated with a slightly increased risk of Alzheimer's disease (AD) compared with synthetic and hydrophilic statins, suggests a new study based on real-world clinical practice data.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Rachel Soon, 21 Feb 2018

MIMS Pharmacist sits down with pharmacist researcher Dr Mai Chun Wai to find out more about his work in drug discovery, including his investigations of Antarctic soil microorganisms.